Acquisitions - Narrative (Details) $ / shares in Units, $ in Millions |
1 Months Ended | 3 Months Ended | ||||
|---|---|---|---|---|---|---|
|
Mar. 04, 2026
USD ($)
|
Jul. 25, 2025
USD ($)
|
Mar. 31, 2026
USD ($)
$ / shares
|
Jul. 31, 2025
USD ($)
right
$ / shares
|
Mar. 31, 2026
USD ($)
$ / shares
|
Mar. 31, 2025
USD ($)
|
|
| Asset Acquisition [Line Items] | ||||||
| Acquired in-process research and development | $ 584 | $ 1,572 | ||||
| Ventyx Biosciences, Inc | ||||||
| Asset Acquisition [Line Items] | ||||||
| Business acquisition, share price (in dollars per share) | $ / shares | $ 14 | $ 14 | ||||
| Cash paid, net of cash acquired | $ 1,058 | $ 1,100 | ||||
| Verve Therapeutics, Inc. | ||||||
| Asset Acquisition [Line Items] | ||||||
| Business acquisition, share price (in dollars per share) | $ / shares | $ 10.50 | |||||
| Cash paid, net of cash acquired | $ 549 | |||||
| Consideration transferred, number of contingent value rights | right | 1 | |||||
| Contingent value right, additional price per share (in dollars per share) | $ / shares | $ 3.00 | |||||
| Contingent value right, additional price per share, aggregate amount | $ 300 | |||||